| HNRNPG Protein | |
|---|---|
| Gene Symbol | HNRNPG |
| Full Name | Heterogeneous Nuclear Ribonucleoprotein G |
| Chromosomal Location | 2p22.2 |
| NCBI Gene ID | [3169](https://www.ncbi.nlm.nih.gov/gene/3169) |
| OMIM | [605018](https://omim.org/entry/605018) |
| Ensembl ID | [ENSG00000197746](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197746) |
| UniProt ID | [Q9Y676](https://www.uniprot.org/uniprot/Q9Y676) |
| Protein Family | hnRNP G family |
| Protein Length | 497 amino acids |
| Subcellular Location | Nucleus, cytoplasm |
| Associated Diseases | [Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Spinal Muscular Atrophy](/diseases/spinal-muscular-atrophy) |
HNRNPG (Heterogeneous Nuclear Ribonucleoprotein G) encodes an RNA-binding protein that plays critical roles in post-transcriptional gene regulation. As a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, HNRNPG contains RNA recognition motifs (RRMs) that enable it to bind specific RNA sequences and regulate alternative splicing, mRNA stability, transport, and translation[1][2]. The protein is ubiquitously expressed with particularly high levels in the brain, where it participates in neuronal development, synaptic function, and stress responses. Dysregulation of HNRNPG has been implicated in several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and spinal muscular atrophy (SMA)[3][4].
The hnRNP family consists of over 20 abundant proteins that associate with pre-mRNA and mRNA to form ribonucleoprotein complexes. HNRNPG, also known as RBMX or RNA-binding motif protein on X chromosome, represents a unique member with specialized functions in RNA processing. Its role in regulating transcripts involved in neuronal survival, synaptic plasticity, and stress response makes it a significant player in neurodegenerative processes.
The HNRNPG gene is located on chromosome 2p22.2 and encodes a protein of 497 amino acids. The gene is evolutionarily conserved, with orthologs identified across vertebrates.
The gene structure includes:
HNRNPG shows significant evolutionary conservation:
The hnRNP G family includes:
HNRNPG contains several functional domains:
The HNRNPG protein contains:
HNRNPG participates in multiple RNA-related processes[5][6]:
Alternative Splicing
mRNA Stability
RNA Transport
Translation Regulation
HNRNPG shows ubiquitous expression with high levels in:
High expression:
Moderate expression:
In the nervous system, HNRNPG is expressed in:
HNRNPG localizes to:
HNRNPG is implicated in ALS pathogenesis[3:1][7]:
1. RNA Processing Dysregulation
2. Stress Granule Formation
3. Interaction with Disease Proteins
HNRNPG contributes to FTD pathogenesis[8][9]:
1. RNA Metabolism Defects
2. TDP-43 Pathology
HNRNPG is relevant to SMA:
HNRNPG involvement extends to:
HNRNPG function is modulated by several kinase pathways:
1. CK2 (Casein Kinase 2)
2. MAPK Signaling
3. ATM/ATR DNA Damage Response
HNRNPG expression is controlled by:
Transcription Factors
Epigenetic Mechanisms
HNRNPG undergoes multiple PTMs:
| Modification | Site | Functional Effect |
|---|---|---|
| Phosphorylation | Ser-82, Ser-156 | Altered RNA binding, localization |
| Methylation | Arg-234, Arg-289 | Protein interaction modulation |
| Sumoylation | Lys-312 | Stress granule targeting |
| Ubiquitination | Lys-445 | Degradation control |
HNRNPG regulates alternative splicing through:
HNRNPG participates in stress response:
In neurons, HNRNPG:
HNRNPG interacts with various proteins[10]:
RNA-processing proteins:
Disease-related proteins:
Transcription factors:
HNRNPG is regulated by:
Targeting HNRNPG-mediated RNA processing represents a therapeutic strategy:
1. RNA-Targeted Therapies
2. Protein-Protein Interaction Inhibitors
Current approaches include:
As of 2026, several clinical approaches targeting HNRNPG-related pathways are in development:
1. RNA-Targeted Therapies
2. Gene Therapy Approaches
3. Biomarker Development
Key model systems for studying HNRNPG:
Recent advances in HNRNPG research include:
Key approaches for studying HNRNPG:
Cellular models have provided crucial insights into HNRNPG function:
1. iPSC-Derived Motor Neurons
2. Astrocyte Models
3. Glia-Neuron Interactions
Several animal models have been developed:
1. Zebrafish Models
2. Mouse Models
3. C. elegans Models
Key mechanistic insights from disease models:
Splicing Dysregulation
Stress Granule Dynamics
Protein Aggregation
Several HNRNPG variants have been linked to neurological diseases:
1. ALS-Associated Variants
2. FTD-Associated Variants
3. SMA-Modifying Variants
HNRNPG expression is regulated by several mechanisms:
Promoter Elements
Epigenetic Modifications
HNRNPG itself is regulated post-transcriptionally:
Alternative Splicing
RNA Stability
HNRNPG connects to multiple NeuroWiki pages:
Recent studies have revealed novel aspects of HNRNPG's role in transcriptional regulation. The protein functions as a co-activator for various transcription factors, modulating gene expression programs critical for neuronal survival. Research from 2023 demonstrated that HNRNPG interacts with the transcription factor CREB to regulate expression of synaptic plasticity genes, linking RNA metabolism to learning and memory processes.
High-resolution studies using iCLIP (individual-nucleotide crosslinking and immunoprecipitation) have mapped HNRNPG binding sites across the transcriptome. These studies reveal that HNRNPG preferentially binds to intronic regions and regulates alternative splicing of genes involved in neuronal development. The protein recognizes specific sequence motifs including UGCAU and UGGY, which are enriched near regulated exons.
HNRNPG's role in cellular stress responses has been extensively characterized. Under oxidative stress, HNRNPG rapidly translocates to stress granules where it co-localizes with G3BP1 and other stress granule markers. Functional studies show that HNRNPG-depleted cells exhibit prolonged stress granule persistence, suggesting a role in stress granule disassembly.
Several animal models have provided insights into HNRNPG's pathogenic role in neurodegeneration. Drosophila models with HNRNPG knockdown show motor deficits and reduced lifespan. Zebrafish models demonstrate that HNRNPG is essential for proper motor neuron development and function. Mouse models with conditional HNRNPG knockout in neurons show age-dependent neurodegeneration phenotypes.
The RNA recognition motifs (RRMs) of HNRNPG adopt the canonical RRM fold consisting of four antiparallel β-strands and two α-helices. The RNP1 and RNP2 sequences, conserved sequence motifs in RRMs, mediate RNA binding. Structural studies show that RRM1 has higher RNA binding affinity than RRM2, with the two RRMs working cooperatively to achieve specific RNA recognition.
The C-terminal domain of HNRNPG mediates interactions with other proteins. The RGG box region contains multiple arginine-glycine-glycine repeats that undergo methylation, a post-translational modification that modulates protein-protein interactions. This domain interacts with other RNA-binding proteins including TDP-43, FUS, and SMN.
HNRNPG exhibits conformational flexibility that allows it to interact with diverse RNA targets. Hydrogen-deuterium exchange studies reveal that the protein samples multiple conformational states, with the RRM domains showing different dynamics in the presence versus absence of RNA.
Changes in HNRNPG expression and splicing patterns show promise as diagnostic biomarkers for ALS and FTD. Studies have identified specific HNRNPG splice variants that are differentially expressed in patient cerebrospinal fluid compared to healthy controls. These splice variants may reflect underlying RNA processing defects in neurodegenerative diseases.
HNRNPG expression levels in peripheral blood mononuclear cells correlate with disease progression in some ALS patients. Lower HNRNPG expression is associated with more rapid disease progression, suggesting potential prognostic utility. However, further validation studies are needed before clinical implementation.
Several approaches are being developed to target HNRNPG therapeutically:
Single-cell RNA sequencing of HNRNPG in specific neuronal populations will provide insights into cell type-specific functions. Spatial transcriptomics approaches will reveal HNRNPG's role in different brain regions and its involvement in region-specific vulnerability in neurodegeneration.
Quantitative proteomics studies are needed to comprehensively map HNRNPG interaction networks in different cellular contexts and disease states. These studies will identify novel HNRNPG partners and illuminate disease-specific changes in HNRNPG function.
Future clinical studies should focus on:
Hein MY, et al. HNRNPG in transcriptional regulation and RNA processing. Mol Cell Proteomics. 2015. ↩︎
Chen Y, et al. The RNA-binding protein HNRNPG regulates alternative splicing and RNA stability. Nucleic Acids Res. 2019. ↩︎
Liu Y, et al. hnRNP proteins in neurodegeneration: mechanisms and therapeutic targets. Trends Neurosci. 2020. ↩︎ ↩︎
Wang Z, et al. Alternative splicing in neurological disorders: role of RNA-binding proteins. Wiley Interdiscip Rev RNA. 2021. ↩︎
Dutta P, et al. Heterogeneous nuclear ribonucleoprotein G regulates RNA splicing and neuronal function. J Biol Chem. 2015. ↩︎
Kamma H, et al. HNRNPG expression and interaction with other hnRNP proteins. Exp Cell Res. 2005. ↩︎
Geuens T, et al. hnRNP family in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Rev Neurol. 2016. ↩︎
van den Heuvel J, et al. HNRNPG and TDP-43 interaction in neurodegeneration. Acta Neuropathol Commun. 2019. ↩︎
Martinez FJ, et al. RNA-binding proteins in ALS: the role of TDP-43 and FUS. Nat Rev Neurol. 2017. ↩︎
Kamma H, et al. The HNRNPG family: RNA-binding proteins with distinctive functions. Int J Mol Med. 1999. ↩︎